secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-06-25T23:59:59+00:00
Accession:  0001493152-24-025102
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics updates Nasdaq compliance status after $7.5M private placement; hearing June 27
--------------------------------------------------------------------------------

- Received Nasdaq deficiency notice on May 16, 2024 for failing to meet $2.5M equity requirement.
- Completed $7.5M private placement on June 10, 2024; believes it now meets equity requirement.
- Hearing before Nasdaq Panel scheduled June 27, 2024; decision expected within 30 days.
- Company acknowledges it will need additional equity capital to maintain ongoing compliance.
- Risk of delisting if unable to demonstrate compliance; could materially affect stock price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224025102/0001493152-24-025102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224025102/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-025102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer